Glofitamab therapy for diffuse large B cell lymphoma: latest updates from the 2022 ASH Annual Meeting
Abstract Over one-third of B cell lymphomas are not effectively treated by R-CHOP chemotherapy. When lymphoma relapses or is refractory, the prognosis becomes very poor. Due to this fact, there is an urgent and clear requirement for a more effective, novel treatment option. Glofitamab is a CD20xCD3...
שמור ב:
| Principais autores: | , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BMC
2023-03-01
|
| סדרה: | Journal of Hematology & Oncology |
| גישה מקוונת: | https://doi.org/10.1186/s13045-023-01420-w |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|